Pharmaceuticals China

China Osteoarthritis Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Osteoarthritis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Joint, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $766.7 Mn Placeholder estimate
Estimate 2025 $830.3 Mn 8.1% of the global market
Projected 2034 $1.70 Bn 105% Adds $871.4 Mn over 9 forecast years
CAGR 2025–2034 8.3% Faster than 32% of 180 Pharmaceuticals markets here
Key players 5
  • China is 8.06% of the global market.
  • In APAC, the largest is China (this report) at $830.3 Mn.
  • Fastest growing: India at 10.3% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$871.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Osteoarthritis Treatment Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $766.7 Mn — —
2025 (base) $830.3 Mn +$63.6 Mn —
2026 (forecast) $899.2 Mn +$68.9 Mn +8.3%
2027 (forecast) $973.8 Mn +$74.6 Mn +17.3%
2028 (forecast) $1.05 Bn +$80.8 Mn +27%
2029 (forecast) $1.14 Bn +$87.5 Mn +37.6%
2030 (forecast) $1.24 Bn +$94.8 Mn +49%
2031 (forecast) $1.34 Bn +$102.7 Mn +61.4%
2032 (forecast) $1.45 Bn +$111.2 Mn +74.7%
2033 (forecast) $1.57 Bn +$120.4 Mn +89.2%
2034 (forecast) $1.70 Bn +$130.4 Mn +105%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Osteoarthritis Treatment Market Analysis at a glance
Market size, 2025$830.3 Mn placeholder estimate
Forecast, 2034$1.70 Bn placeholder estimate
Growth (CAGR), 2025–20348.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledOsteoarthritis Therapeutics
SegmentsTreatment, joint and end user (see all)
Key playersPfizer Inc., Sanofi, Bioventus, Anika Therapeutics, Inc, Ferring Pharmaceuticals (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials43 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Osteoarthritis Treatment Market Analysis Executive Summary

Osteoarthritis treatments ease joint pain and stiffness with medicines, injections, physical therapy and surgery.

Key segments of the osteoarthritis Treatment market include treatment (NSAIDs, Corticosteroid Injections and Hyaluronic Acid Injections) and joint (Knee, Hip and Hand).

Bar chart: China Osteoarthritis Treatment market size, 2024–2034, placeholder estimates. $766.7 Mn in 2024, $830.3 Mn in 2025 and $1.70 Bn in 2034, 8.3% CAGR.
China Osteoarthritis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Osteoarthritis Treatment Market Dynamics

Market Growth Drivers

An ageing and more active population, more sports injuries, rising obesity and better implants and procedures are driving the osteoarthritis Treatment market.

Opportunity

Same-day joint surgery, robotics, smart implants and biologic treatments give the osteoarthritis Treatment market room to grow.

Market Restraints

High procedure costs, pricing pressure from hospitals, recalls and long recovery times hold back the osteoarthritis Treatment market.

Competitive Landscape for Osteoarthritis Treatment Market in China

The osteoarthritis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Osteoarthritis Treatment Market in China

Osteoarthritis Treatment in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 43 studies on Osteoarthritis Treatment that are recruiting, active or about to start in China.⁠[3] People aged 65 and over: 14.9% of people in 2025, the latest World Bank figure for China.⁠[4]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

[4] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for osteoarthritis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Osteoarthritis Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 16 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Osteoarthritis Treatment in context

China compared

  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[1]
  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[3]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Osteoarthritis Treatment market in China?
Placeholder estimate: about $830.3 Mn in 2025, rising to about $1.70 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Osteoarthritis Treatment market in China growing?
Placeholder estimate: about 8.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Osteoarthritis Treatment market report cover?
The report splits the market by treatment (NSAIDs, Corticosteroid Injections, Hyaluronic Acid Injections, Regenerative Therapies), joint (Knee, Hip, Hand, Spine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Osteoarthritis Treatment market?
Key players include Pfizer Inc., Sanofi, Bioventus, Anika Therapeutics, Inc and Ferring Pharmaceuticals.
What is driving the Osteoarthritis Treatment market?
An ageing and more active population, more sports injuries, rising obesity and better implants and procedures are driving the osteoarthritis Treatment market.
Who regulates Osteoarthritis Treatment in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Osteoarthritis Treatment are running in China?
43 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
What does World Bank report for China?
People aged 65 and over: 14.9% of people in 2025, the latest World Bank figure. Source: World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
How much research is published on Osteoarthritis Treatment?
PubMed lists 511 papers on Osteoarthritis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on bones and joints and pain

See the topic